Glycated albumin (GA) is emerging as an alternative marker to glycated haemoglobin (HbA1c) for monitoring glycemic control, proving particularly useful in clinical settings where HbA1c loses reliability, such as in haemoglobinopathies, diabetic nephropathy, and during pregnancy. This review explores the established clinical applications and future perspectives of GA, providing insights for its potential integration into endocrinology practice.
Albumina glicata: nuovo parametro di controllo glicemico nella pratica endocrinologica
Gianluca Marzi;Martina Verrienti;Maria Chiara Zatelli;Maria Rosaria Ambrosio
2026
Abstract
Glycated albumin (GA) is emerging as an alternative marker to glycated haemoglobin (HbA1c) for monitoring glycemic control, proving particularly useful in clinical settings where HbA1c loses reliability, such as in haemoglobinopathies, diabetic nephropathy, and during pregnancy. This review explores the established clinical applications and future perspectives of GA, providing insights for its potential integration into endocrinology practice.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
